News

Beneficial impacts of SGLT-2 Inhibitors on Cardiovascular Disease

After several clinical trials associated with SGLT-2 inhibitors, this anti-diabetic drug class of medications is now linked to providing beneficial impacts on cardiovascular disease. Sodium-glucose cotransporter-2 inhibitors, also known as SGLT2 inhibitors, are antidiabetic drug classes that exert their function...

2-24-2022

FDA approves first Lupus treatment in a decade

Earlier this year, the FDA approved the first new treatment for Lupus since 2011. This is a major win for the millions of patients who are impacted by this condition, and the advocacy groups, plans, and providers who serve them....

11-24-2021

Abarca Health: FDA approves first Lupus treatment in a decade

Jason Borschow qualified as an Endeavor Outlier

SAN JUAN, PR -- Jason Borschow, President and CEO of Abarca, has qualified as an Endeavor Outlier, an exclusive global group of high-impact entrepreneurs from the prestigious Endeavor, a global network with the mission of unlocking the transformational power of entrepreneurship by...

9-24-2021

Abarca Health: Jason Borschow qualified as an Endeavor Outlier